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ABSTRACT
When patients seek medical help, they expect to be protected and that healthcare decisions preserve
their safety – they expect to receive more beneﬁt than harm. Harm can be caused through both action
and inaction, for example by failing to provide adequate therapy because of cost constraints. Restrictions
on the use of antibiotics that prevent or discourage the use of the best available treatment may jeopardise
the health ⁄ recovery of patients, and undermine their trust in their doctor. What the public and patients
may be less clear about is the complex interplay between competing priorities; providing quality care vs.
ensuring cost efﬁciencies in a public healthcare system, which is under increasing pressure to deliver
comprehensive care. As new technology becomes available, and the need for and expectations of
healthcare increase, the pressure on governments to manage soaring healthcare costs may impact on the
care that patients receive, as individuals, from their doctor. Patients vary in their desire to be involved in
decisions about their treatment. Some are happy to trust the professionals; others want information from
various sources, an open dialogue about the options and the ultimate right to make the best choice for
themselves. Governments are keen to have more empowered patients, in the belief that this will drive up
standards of care and increase patient satisfaction. This may result in greater pressure from patients for
the best treatments to be made available.
Keywords Antibiotic resistance, ethics, optimal antibiotic prescribing, physician–patient communica-
tion, rational antibiotic prescribing, review
Clin Microbiol Infect 2006; 12 (Suppl. 5): 10–15
INTRODUCTION
Patients rely on the help of experts in managing
their health. When they seek help, their expecta-
tion is to be protected and that healthcare deci-
sions preserve their safety; they expect to receive
more beneﬁt than harm. These expectations are
directed towards government, healthcare sys-
tems, healthcare providers and pharmaceutical
companies. Patients expect healthcare profes-
sionals to be competent and to do the best they
can for them, within a healthcare system that has
measures in place to protect patients. They expect
pharmaceutical companies to produce medicines
that are safe and effective, and via licensing, that
the relevant authorities have independently
assessed the medicine’s suitability for widespread
use. In addition, patients have an expectation of
affordable medicines or access to medicines that
can be funded by their healthcare systems.
This paper examines some of the key aspects of
healthcare from the patient’s perspective, inclu-
ding trends toward greater patient empower-
ment. Antibiotic prescribing restrictions are a
reality in most healthcare systems, but patients
may not be aware of these restrictions or the
underlying reasons for them (cost, resistance,
safety). The implications of this dissociation for
the patient–physician relationship are considered,
as well as the risks and consequences of a return
to the preantibiotic era if new antibiotics do not
become available.
BETTER INFORMED PATIENTS?
In the last decade, there has been an explosion
in the amount of medical information available
to patients, particularly through the world wide
web. However, there is considerable variation in
the volume of information about different med-
ical conditions, and most is related to common,
chronic diseases such as cancer, diabetes and
heart disease (Fig. 1). Even for acute diseases,
such as common respiratory tract infections,
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‘hits’ run into several hundred thousand. Nev-
ertheless, patients may believe that their time is
better spent elsewhere, rather than looking
through this information. In a questionnaire
study of patients attending a genitourinary
clinic, although 41% had access to the internet,
of these, only 10% had used it to ﬁnd out more
about their problem [1].
There is also considerable variability in the
quality of information available on the web, and
patients may ﬁnd it difﬁcult to distinguish
between fact and ﬁction, and opinion and evi-
dence. Literacy may also be an issue for a
signiﬁcant number of patients. In a 1999 survey
of 50 patient educational texts downloaded from
the web, the average reading level of the texts was
approximately 10th grade (about 16 years of age)
[2]. In comparison, in a survey of 26 000 people
across the USA, the average reading level was 8th
grade (about 14 years of age) and 49.5% were
functionally illiterate or only marginally literate.
Thus, up to 44 million people in the USA cannot
understand basic written material and, when that
material is of a technical nature, such as that
related to health and medicines, an even larger
number will have difﬁculties. Indeed, poor health
literacy may be more the norm than the exception.
Therefore, the majority of information on the web
is not comprehensible to a large proportion of the
patient population [3].
In the USA, direct-to-consumer advertising
has been expanded since 1997 when the Food
and Drug Administration decided to ease
restrictions on TV advertising. Between 1996
and 1998, pharmaceutical company expenditure
on direct-to-consumer advertising nearly dou-
bled from US $ 600 million to US $ 1.1 billion
[4] and had increased to US $ 2.47 billion by
2000 [5]. The rationale behind direct-to-con-
sumer advertising is that it provides patients
with information regarding drug therapies and
empowers them to make more rational health-
care decisions. However, balance in advertising
may be lacking and an artiﬁcial demand for
drugs may be created. The USA and New
Zealand are currently the only developed coun-
tries in which direct-to-consumer advertising is
permitted; it has both supporters and detractors,
and should be looked at as an ongoing experi-
ment.
There is some evidence that physicians are
sensitive to requests from patients for particular
medicines. In a survey of prescribing decisions
by 78 physicians for 1431 patients in the USA
and Canada, patients who requested a prescrip-
tion were more likely to receive one (odds ratio
8.7; 95% conﬁdence interval [CI], 5.4–14.2) [5].
However, when physicians were asked to con-
sider whether they would prescribe that drug
for a patient with the same condition, 43%
showed some reservation (odds ratio 5.4; 95%
CI, 3.5–8.5) compared with only 12% in the case
of drugs not requested by patients [5]. This
could indicate that patients can and do inﬂu-
ence their physicians’ prescribing decisions, and
that physicians are more distrustful of the
prescribing outcome when patients have exerted
some inﬂuence within the consultation.
Despite the proliferation of medical informa-
tion aimed at patients on the world wide web,
in the media and, at least in the USA, through
advertising, most patients still regard their
doctor as the most useful source of information
about prescribed medicines. In a 2004 survey of
1864 patients in the National Health Service in
the UK, 69% believed their doctor was a useful
source of information compared with 52% for
pharmacists, 30% for pack leaﬂets and 14% for
the internet [6]. Thus, physicians still play a key
role in informing and educating patients regard-
ing their medicines, not only so that they are
able to take their medicines effectively, but also
so that they are able to understand the beneﬁts
and risks of the recommended therapy. Perhaps
the effect of internet-based information is more
subtle, requiring healthcare providers to adjust
their role according to patient needs: on some
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Fig. 1. ‘Hits’ on http://www/google.com for common
medical terms, including the major respiratory tract infec-
tions.
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occasions as a ﬁlter and on others as a conduit,
a technical reference or simply a reservoir [7].
However, in some cases, the physician may
react negatively to informed patients, regarding
them as a challenge and employing strategies
that reinforce more traditional power roles [8].
The success of the ‘informed patient’ model
relies on effective and open communication,
with the physician focused on his ⁄her patients
and open to meeting their varying needs.
INFORMED CONSENT, NEGLIGENCE
AND HARM
Informed consent is a cultural construct, which in
most countries has been incorporated into law in
some form. It represents the enactment of a
patient’s right to autonomy (i.e., that all people
have free will and a right to control their own
lives and bodies). Physicians can be prosecuted
under various statutes if they act either against a
patient’s wishes, or keep a patient ignorant of the
risks and consequences of their actions [9].
Overall, there are six main areas where physi-
cians have a responsibility to provide information
to justify informed consent (Table 1). The physi-
cian must be careful to explain risks that may
seem obvious, but may not be obvious to the
patient, or that are rare but serious, as events that
are rare in a population do happen in individual
patients. However, there should be a balance
between the information required to make an
informed decision, and a listing of all the possible
negative aspects of a treatment which may cause
patients to become alarmists [9].
Interestingly, in a UK survey of 456 patients
who had been prescribed a new medicine in the
last 12 months, although 96% of patients said that
they knew how and when to take the medicine,
and 90% knew how long to take the medicine,
when it came to the factors required for making
an informed decision, patient understanding was
less well developed: 89% thought they under-
stood the beneﬁts of the medicine, 76% the
potential adverse effects of the medicine and only
50% knew of other possible choices, such as a
different medicine or an alternative treatment [6].
The question arises as to whether these patients
are, in fact, providing informed consent.
Failure to provide patients with the information
needed to make informed consent to therapy may
be considered negligence. Negligence can also be
claimed where a patient has failed to receive a
reasonable amount of care during intervention.
However, the picture becomes more complicated
when no care is provided.
While a patient needs to give informed consent
in order to receive an intervention, the situation is
less clear when the decision is taken not to
provide a potentially useful intervention. How-
ever, if the physician recommends that no action
be taken, then the risks of and alternatives to this
recommendation also need to be explained. In
medical terms, failure to provide therapy is not
generally considered to be harmful. Legally,
negligence can theoretically occur if a patient is
denied therapy, though this is rarely prosecuted
successfully, particularly in the case of public
health systems where the statutory duty may
prevent consideration of the duty to the individ-
ual. In addition, if the negative consequences of
withholding therapy are not ‘forseeable’, there is
no legal justiﬁcation for negligence.
Ethically, the position is somewhat different.
In the absence of therapy, if the patient’s
condition worsens, then the patient has been
harmed. If the physician believed that the
patient could have beneﬁted from therapy, but
withheld it for whatever reason, then the patient
has been harmed. From the patient’s perspec-
tive, a negative outcome due to inappropriate
intervention or negligent care is essentially the
same as a negative outcome due to failure to
provide care.
PATIENT INVOLVEMENT IN
DECISION MAKING
Models of patient–physician relationships range
from the traditional paternalistic model where the
doctor makes all the decisions, through shared
decision making based on a dialogue between the
Table 1. Information required for patients to provide
informed consent [9]
Nature of the disease and the proposed treatment or
surgery
Chances of success based on medical knowledge
Risks of the proposed treatment or procedure
Adverse effects of the proposed treatment or procedure
Reasonable alternatives and their chances of success,
risks and adverse effects
Consequences of deciding not to proceed with the
recommended course of treatment
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patient and physician, to the informative model
where the patient makes decisions based on
information provided by the physician (Fig. 2).
Different patients will place themselves at differ-
ent points along this spectrum of involvement in
decision making. It should be remembered that
preference for an interactive patient-centred
approach to the consultation may not necessarily
be consistent with a preference for shared decis-
ion making. In other words, information seeking
by the patient is a process separate from decision
making [10,11]. In a review of patient survey data
from Canada, the USA and Israel, over 92% of
patients and nonpatients stated that they wanted
to be informed about their illnesses [11]. How-
ever, there was considerable variability in the
patients’ preference for being involved in decision
making [11].
The preference for shared decision making
declines as patients get older [11,12]. It is not
clear whether this is due to an increasing level of
dependency in elderly patients or whether it is a
‘generational’ effect of changing attitudes towards
the role of doctors in society. Patients who are
sicker, or who have more serious disease, also
tend to want to be less involved in actual decision
making [11], as do patients who are less well
educated or from lower socio-economic groups
[11]. Thus, the preference for shared decision
making appears to be related to the vulnerability
of the patient and the discrepancy in power
between the patient and the doctor. Where
patients feel themselves to be on a more equal
footing with their physician, they are more will-
ing to share responsibility for decisions about
their health. However, the vast majority of the
variation in participatory preference among
patients is not explained by these factors, and
health systems need to be careful about making
assessments of patient need by ‘pigeonholing’
patients into these groups.
A number of studies have shown that patients
who are better informed about their illness, who
are aware of different treatment options and who
are able to communicate effectively with their
physicians have better outcomes [13–16].
Although healthcare systems appear to want
patients to take more responsibility for their
health and be more involved in making decisions
and choices, in reality these choices are limited
and controlled. For chronic diseases, such as
multiple sclerosis, or life-threatening illness, such
as infection with human immunodeﬁciency virus
(HIV) or cancer, patients have often grouped
together to campaign for access to new medicines.
These medicines are often more expensive than
the standard treatments and may, in some cases,
such as Alzheimer’s therapies, have marginal
beneﬁts when studied in clinical trials, despite
considerable improvement in some individual
patients. Although patients may act in groups,
their interest in new therapies is at the level of the
individual, and the beneﬁt it might afford them,
and is not measured across populations.
Overall, there appears to be a trend toward
increased patient involvement, both in terms of
the information patients want regarding their
illness and treatment, and in their willingness to
be involved in decision making. Thus, patients are
becoming an increasingly powerful group, and
are exerting their rights as ‘consumers’ of health-
care more actively. As choice in healthcare
expands, there will be increasing opportunities
for patients to apply pressure for changes in
services, both individually through their physi-
cians and in groups through patient lobbying
organisations.
IMPLICATIONS OF ANTIBIOTIC
RESTRICTONS
Patients value therapies that will not only cure
them, but are easy to take, will resolve their
symptoms quickly and enable them to return to
their normal activities as soon as possible. For
example, in the case of acute exacerbation of
chronic bronchitis, differences in antibiotic ther-
apy can impact on the time between exacerba-
tions, a critically important outcome for the
patient [17–19]. In contrast, healthcare systems
and government pricing and reimbursement
authorities may feel that these broader health
outcomes have only a marginal beneﬁt over cost –
they tend to look more at the acquisition costs of
antibiotics and overall clinical efﬁcacy data,
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Shared decision
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patient participates in
decision by expressing
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options
Informative
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decides
Fig. 2. Range of patient involvement in decision making.
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which in many cases are generated from studies
designed to show equivalence between therapies.
Thus, the ‘best’ therapy from the patient’s per-
spective may not be the ‘best’ therapy from the
payor’s perspective.
Since the payor has restricted antibiotic options
based on their perspective, and this conﬂicts with
the patient’s perspective, the physician is caught
somewhat in the middle. Should patients be told
that the medicine that may eradicate their infec-
tion more rapidly, resolve their symptoms more
quickly, has a more convenient dosage regimen,
but with no additional risk of adverse events, is
not available to them but they are allowed to have
another agent, which will probably cure their
infection, but more slowly or with the possibility
of side-effects? Even if these discrepancies are
discussed with the patient, it is likely that the
patient will be kept in ignorance of the signiﬁcant
issue of cost difference between the two treat-
ments. In the case of antibiotics, there is also the
very real concern that the slower-acting, more
side-effect prone, less expensive and less con-
venient agent may not be effective because of high
levels of resistance. This raises the question of the
‘best therapy’ for the patient.
It may, at ﬁrst, seem pointless to tell patients
about another therapy that is not available to
them or restricted in some way. However, in
some cases, the patient may choose to make a
co-payment to obtain the therapy or may decide to
obtain a private prescription. In addition, under
social healthcare systems and health maintenance
organisations, where services are ‘rationed’,
patients should know why their treatment may
be delayed or unavailable, irrespective of whether
the consequences are several extra days off work, a
worsened long-term outcome or a higher risk of
mortality. Fundamentally, patients have a right to
the information that they need to provide
informed consent, including information on treat-
ment alternatives, even if these are not those
endorsed by the healthcare system, as well as
information on the consequences of no treatment.
In short, only the patient is able to judge accurately
his or her own priorities and needs.
Balanced against the patient’s immediate needs
for ‘best’ therapy is the need to ensure that new
antibiotics are continually being developed in
order to combat increasing antimicrobial resist-
ance. There is a dilemma here also. Antibiotic
prescribing needs to be optimised to preserve
future efﬁcacy. However, if payors are restricting
antibiotic use either to control costs or with the
aim of controlling resistance, then this has an
upstream impact on pharmaceutical develop-
ment. Pharmaceutical companies will not develop
new drugs when their use may be excessively
regulated. Unless pharmaceutical companies can
have a reasonable expectation of a proﬁt that will
cover the costs of research and development of
both approved products and products that may
fail during the development process, new medi-
cines will not be developed. Thus, restricting
antibiotic usage in the short term may, in the
longer term, further reduce the availability of
effective antimicrobial agents (see Power, this
supplement, page 25).
Healthcare systems often support their recom-
mendations for antibiotic prescribing with a suite
of barriers, incentives and penalties directed
towards physicians. Patient education campaigns
regarding the risk of overprescribing antibiotics
often accompany these measures. Such interven-
tions have an implicit impact on the physician–
patient relationship. When the physician is
expected to enforce the agenda of the healthcare
system, can he ⁄ she also be acting in the best
interest of patients? If patients were aware of
these potentially conﬂicting agendas, would their
trust in the physician be eroded? In addition,
patients may be less likely to present early if they
have an expectation that antibiotic therapy will be
denied, and may regard visiting a doctor as a last
resort. In a certain proportion of patients, this may
result in adverse outcomes, such as hospitalisa-
tion or increased mortality (see Price, this supple-
ment, page 3).
CONCLUSIONS
It is debatable whether the increase in the avail-
ability of patient information is fuelling the
increased desire of patients to take part in
decision making regarding their treatment, or
vice versa. Certainly, there is a trend toward
younger, more educated patients to want to share
decision making with their physician. In seeking
best care, patients may challenge the traditional
paternalistic role of the physician. Also, they may
become more active consumers of healthcare
through involvement in patient organisations.
It is important that the autonomy of patients is
respected and that their right to informed consent
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is interpreted in broad terms – more expansively
than perhaps in the past. Patients expect and
should obtain all the information they need in
order to accept or make decisions regarding their
healthcare. Also, it should be remembered that
not only can patients be harmed by adminis-
tration of unwarranted or less effective therapy,
through exposure to unnecessary adverse events,
but they can also be harmed should the best
therapy be denied when needed. With greater
access to healthcare information, patients may be
aware of competing agendas within the health-
care system that deny what they perceive to be
the ‘best’ medicines. Physicians must start a
dialogue with patients, making their roles as both
gatekeepers for the health system and providers
of care to individual patients explicit. Only an
honest and open approach can preserve patient
trust in the profession.
Finally, in the case of antibiotics, governments
and healthcare systems should recognise the full
range of their responsibilities. Both must strive to
strike a balance between the needs of patients for
fast, effective therapies, which may be a newer
generation and thus more expensive, the longer
term preservation of antimicrobial efﬁcacy in the
face of increasing resistance, and support for new
medicines so that the development of potentially
useful advances is not stiﬂed. Concentrating on
prescribing volume and the cost of agents is too
simplistic a model to achieve this balance and
more complex models that integrate the patient’s
viewpoint need to be developed.
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